• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Covid-19 and Patients with IBD: Who Is at Highest Risk for Severe Complications?

作者信息

Horst Sara

机构信息

Division of Gastroenterology, Hepatology, and Nutrition, Vanderbilt University Medical Center, Nashville, USA.

出版信息

Dig Dis Sci. 2022 Apr;67(4):1090-1091. doi: 10.1007/s10620-021-07106-y. Epub 2021 Jun 28.

DOI:10.1007/s10620-021-07106-y
PMID:34181167
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8237777/
Abstract
摘要

相似文献

1
Covid-19 and Patients with IBD: Who Is at Highest Risk for Severe Complications?新冠病毒-19与炎症性肠病患者：谁发生严重并发症的风险最高？
Dig Dis Sci. 2022 Apr;67(4):1090-1091. doi: 10.1007/s10620-021-07106-y. Epub 2021 Jun 28.
2
Therapies for inflammatory bowel disease do not pose additional risks for adverse outcomes of SARS-CoV-2 infection: an IG-IBD study.治疗炎症性肠病并不会增加 SARS-CoV-2 感染不良结局的风险：一项 IG-IBD 研究。
Aliment Pharmacol Ther. 2021 Dec;54(11-12):1432-1441. doi: 10.1111/apt.16663. Epub 2021 Oct 25.
3
Letter: risk of severe COVID-19 outcomes associated with inflammatory bowel disease medications-reassuring insights from the United Kingdom PREPARE-IBD multicentre cohort study.信件：炎症性肠病药物与严重 COVID-19 结局相关的风险-来自英国 PREPARE-IBD 多中心队列研究的令人安心的见解。
Aliment Pharmacol Ther. 2021 Jun;53(11):1236-1240. doi: 10.1111/apt.16349.
4
Inflammatory bowel disease and SARS-CoV-2 pandemic: current knowledge and recommendations.炎症性肠病与 SARS-CoV-2 大流行：现有知识和建议。
Scand J Gastroenterol. 2021 Jun;56(6):656-660. doi: 10.1080/00365521.2021.1902561. Epub 2021 Mar 25.
5
Interim analysis of a multicenter registry study of COVID-19 patients with inflammatory bowel disease in Japan (J-COSMOS).日本 COVID-19 合并炎症性肠病患者多中心登记研究的中期分析（J-COSMOS）。
J Gastroenterol. 2022 Mar;57(3):174-184. doi: 10.1007/s00535-022-01851-1. Epub 2022 Jan 28.
6
Impact of immunosuppressants on SARS-CoV-2 infection in elderly patients with inflammatory bowel disease.免疫抑制剂对老年炎症性肠病患者感染 SARS-CoV-2 的影响。
Aging Clin Exp Res. 2021 Aug;33(8):2355-2359. doi: 10.1007/s40520-021-01917-9. Epub 2021 Jun 23.
7
Clinical Outcomes of COVID-19 and Impact on Disease Course in Patients with Inflammatory Bowel Disease.COVID-19 临床结局及其对炎症性肠病患者疾病进程的影响。
Can J Gastroenterol Hepatol. 2021 Nov 30;2021:7591141. doi: 10.1155/2021/7591141. eCollection 2021.
8
Care of the Patient With IBD Requiring Hospitalisation During the COVID-19 Pandemic.COVID-19 大流行期间需要住院治疗的 IBD 患者的护理。
J Crohns Colitis. 2020 Oct 21;14(14 Suppl 3):S774-S779. doi: 10.1093/ecco-jcc/jjaa150.
9
A Seroprevalence Study of Anti-SARS-CoV-2 Antibodies in Patients with Inflammatory Bowel Disease during the Second Wave of the COVID-19 Pandemic in Italy.意大利第二波新冠疫情期间炎症性肠病患者抗SARS-CoV-2抗体血清流行率研究
Medicina (Kaunas). 2021 Oct 1;57(10):1048. doi: 10.3390/medicina57101048.
10
Low prevalence of SARS-CoV-2 infection in inflammatory bowel disease.炎症性肠病中 SARS-CoV-2 感染的低流行率。
Eur Rev Med Pharmacol Sci. 2021 Mar;25(5):2418-2424. doi: 10.26355/eurrev_202103_25283.

引用本文的文献

1
The Impact of Inflammatory Bowel Diseases and Related Medications on COVID-19 Severity and Outcome: A Tertiary Referral Center Experience from Turkey.炎症性肠病及其相关药物对 COVID-19 严重程度和结局的影响：来自土耳其的一家三级转诊中心的经验。
Turk J Gastroenterol. 2022 Dec;33(12):1025-1032. doi: 10.5152/tjg.2022.22059.

本文引用的文献

1
Presence of Comorbidities Associated with Severe Coronavirus Infection in Patients with Inflammatory Bowel Disease.炎症性肠病患者严重冠状病毒感染相关合并症的存在。
Dig Dis Sci. 2022 Apr;67(4):1271-1277. doi: 10.1007/s10620-021-07104-0. Epub 2021 Jun 28.
2
Are Patients With Inflammatory Bowel Disease at an Increased Risk of Developing SARS-CoV-2 than Patients Without Inflammatory Bowel Disease? Results From a Nationwide Veterans' Affairs Cohort Study.炎症性肠病患者感染 SARS-CoV-2 的风险是否高于非炎症性肠病患者？一项全国退伍军人事务队列研究的结果。
Am J Gastroenterol. 2021 Apr;116(4):808-810. doi: 10.14309/ajg.0000000000001012.
3
Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD.英夫利昔单抗与 IBD 患者对 BNT162b2 和 ChAdOx1 nCoV-19 SARS-CoV-2 疫苗的免疫原性降低有关。
Gut. 2021 Oct;70(10):1884-1893. doi: 10.1136/gutjnl-2021-324789. Epub 2021 Apr 26.
4
Effect of IBD medications on COVID-19 outcomes: results from an international registry.IBD 药物对 COVID-19 结局的影响：来自国际注册研究的结果。
Gut. 2021 Apr;70(4):725-732. doi: 10.1136/gutjnl-2020-322539. Epub 2020 Oct 20.
5
Systematic Review on Inflammatory Bowel Disease Patients With Coronavirus Disease 2019: It Is Time to Take Stock.对患有 2019 年冠状病毒病的炎症性肠病患者的系统评价：是时候进行总结了。
Clin Gastroenterol Hepatol. 2020 Nov;18(12):2689-2700. doi: 10.1016/j.cgh.2020.08.003. Epub 2020 Aug 7.
6
The Incidence and Outcomes of COVID-19 in IBD Patients: A Rapid Review and Meta-analysis.炎症性肠病患者中新型冠状病毒肺炎的发病率及转归：一项快速综述与荟萃分析
Inflamm Bowel Dis. 2020 Sep 18;26(10):e132-e133. doi: 10.1093/ibd/izaa170.
7
Risk of Severe Coronavirus Disease 2019 in Patients With Inflammatory Bowel Disease in the United States: A Multicenter Research Network Study.美国炎症性肠病患者发生重症2019冠状病毒病的风险：一项多中心研究网络研究
Gastroenterology. 2020 Oct;159(4):1575-1578.e4. doi: 10.1053/j.gastro.2020.06.003. Epub 2020 Jun 6.
8
Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry.皮质类固醇，而不是 TNF 拮抗剂，与炎症性肠病患者 COVID-19 不良结局相关：来自国际登记处的结果。
Gastroenterology. 2020 Aug;159(2):481-491.e3. doi: 10.1053/j.gastro.2020.05.032. Epub 2020 May 18.
9
Outcomes of COVID-19 in 79 patients with IBD in Italy: an IG-IBD study.意大利 IBD 患者中 79 例 COVID-19 的结局：一项 IG-IBD 研究。
Gut. 2020 Jul;69(7):1213-1217. doi: 10.1136/gutjnl-2020-321411. Epub 2020 Apr 30.